Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 9—September 2015
THEME ISSUE
Emerging Infections Program

Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program

Matthew R. MooreComments to Author  and Cynthia G. Whitney
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 1

Incidence of invasive pneumococcal disease among children <5 years of age, caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Control and Prevention Emerging Infections Program/Active Bacterial Core surveillance, 1998–2013.

Figure 1. Incidence of invasive pneumococcal disease among children <5 years of age, caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Control and Prevention Emerging Infections Program/Active Bacterial Core surveillance, 1998–2013.

Main Article

Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external